

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/21 (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/590,634-Conf. #2264
	Filing Date	May 17, 2007
	First Named Inventor	Bjarne Larsen
	Art Unit	N/A
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	66123US(300586)

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental IDS <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): SIDS (Citation) by Applicant (3 pages) Copies of 28 References Return Receipt Postcard
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	EDWARDS ANGELL PALMER & DODGE LLP		
Signature			
Printed name	Peter C. Lauro		
Date	September 6, 2007	Reg. No.	32,360

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Label No. EM 053203053 US, on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450	
Dated: September 6, 2007	Signature: (Peter C. Lauro)



Application No. (if known): 10/590,634

Attorney Docket No.: 66123(300586)

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EM 053203053 US in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on September 6, 2007
Date

Signature

Peter C. Lauro

Typed or printed name of person signing Certificate

32,360
Registration Number, if applicable

(617) 517-5509
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal Form (1 page)
Supplemental Information Disclosure Statement (SIDS) (2 pages)
SIDS (Citation) by Applicant (28 References) (3 pages)
Copies of 28 References
Return Receipt Postcard

9-7-07

IFW


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Label No. EM 053203053 US, on the date, shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: September 6, 2007

Signature:

Peter C. Lauro
(Peter C. Lauro)

Docket No.: 66123US(300586)
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Bjorne Larsen, et al.

Application No.: 10/590,634

Confirmation No.: 2264

Filed: May 17, 2007

Art Unit: N/A

For: PEPTIDE YY ANALOGUES

Examiner: Not Yet Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants invite the attention of the Patent and Trademark Office to the references and information listed on the attached PTO/SB/08. Applicant respectfully request that the Examiner expressly consider the information during the prosecution of this application and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

In accordance with 37 C.F.R. §1.98(a)(2), Applicants submit herewith copies of the non-patent literature listed on the PTO/SB/08.

In accordance with 37 C.F.R. §1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(a) exists. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


Applicants submit that this Supplemental Information Disclosure Statement is in compliance with 37 C.F.R. §1.98 and request the Examiner to consider the cited references and information.

Applicants file this Supplemental Information Disclosure Statement before issuance of a first Office Action on the merits. Accordingly, Applicants submit that no fees are due for consideration and entry of this Supplemental Information Disclosure Statement. Nevertheless, Applicants authorize the Director to charge any required fee as well as any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105,, under Order No. 66123(300586).

Dated: September 6, 2007

Respectfully submitted,

By



Peter C. Lauro, Esq.

Registration No.: 32,360


EDWARDS ANGELL PALMER & DODGE LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 517-5509

Attorneys/Agents For Applicants



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/590,634-Conf. #2264	
			Filing Date	May 17, 2007	
			First Named Inventor	Bjarne Larsen	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	3	Attorney Docket Number	66123(300586)

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	CA	ADRIAN TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, and Bloom SR. Human distribution and release of a putative new gut hormone, pep-tide YY. Gastroenterology 89: 1070-1077, 1985.			
	CB	ADRAIN TE, Savage AP, Sagor GR, Allen JM, Bacarese-Hamilton AJ, Ta-temoto K, Polak JM, and Bloom SR. Effect of peptide YY on gastric, pancre-atic, and biliary function in humans. Gastroenterology 89: 494-499, 1985.			
	CC	ALLEN JM, Fitzpatrick ML, Yeats JC, Darcy K, Adrian TE, and Bloom SR. Effects of peptide YY and neuropeptide Y on gastric emptying in man. Di-gestion 30: 255-262, 1984.			
	CD	BATTERHAM RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, and Bloom SR. Inhibition of food intake in obese subjects by pep-tide YY3-36. N Engl J Med 349: 941-948, 2003.			
	CE	BATTERHAM RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, and Bloom SR. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418: 650-654, 2002.			
	CF	BERGLUND MM, Hipskind PA, and Gehlert DR. Recent developments in our understanding of the physiological role of PP-fold peptide receptor sub-types. Exp Biol Med (Maywood) 228: 217-244, 2003.			
	CG	BROOME M, Hokfelt T, and Terenius L. Peptide YY (PYY)-immunoreactive neurons in the lower brain stem and spinal cord of rat. Acta Physiol Scand 125: 349-352, 1985.			
	CH	BROWNING KN and Travagli RA. Neuropeptide Y and peptide YY inhibit excitatory synaptic transmission in the rat dorsal motor nucleus of the vagus. J Physiol, 2003.			
	CI	CAMPBELL RE, Smith MS, Allen SE, Grayson BE, Ffrench-Mullen JM, and Grove KL. Orexin neurons express a functional pancreatic polypeptide Y4 re-ceptor. J Neurosci 23: 1487-1497, 2003.			
	CJ	CHEN CH and Rogers RC. Peptide YY and the Y2 agonist PYY-(13-36) in-hibit neurons of the dorsal motor nucleus of the vagus. Am J Physiol 273: R213-218, 1997.			
	CK	FUHLENDORFF J, Johansen NL, Melberg SG, Thogersen H, and Schwartz TW. The antiparallel pancreatic polypeptide fold in the binding of neuropep-tide Y to Y1 and Y2 receptors. J Biol Chem 265: 11706-11712, 1990.			
	CL	GRANDT D, Schimiczek M, Beglinger C, Layer P, Goebell H, Eysselein VE, and Reeve JR, Jr.			
Examiner Signature				Date Considered	

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/590,634-Conf. #2264	
			Filing Date	May 17, 2007	
			First Named Inventor	Bjarne Larsen	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	3	Attorney Docket Number	66123(300586)

		Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 51: 151-159, 1994.	
	CM	GRANDT D, Schimiczek M, Rascher W, Feth F, Shively J, Lee TD, Davis MT, Reeve JR, Jr., and Michel MC. Neuropeptide Y 3-36 is an endogenous ligand selective for Y2 receptors. Regul Pept 67: 33-37, 1996.	
	CN	GRANDT D, Schimiczek M, Struk K, Shively J, Eysselein VE, Goebell H, and Reeve JR, Jr. Characterization of two forms of peptide YY, PYY(1-36) and PYY(3-36), in the rabbit. Peptides 15: 815-820, 1994.	
	CO	GRANDT D, Teyssen S, Schimiczek M, Reeve JR, Jr., Feth F, Rascher W, Hirche H, Singer MV, Layer P, Goebell H, and et al. Novel generation of hor-mone receptor specificity by amino terminal processing of peptide YY. Bio-chem Biophys Res Commun 186: 1299-1306, 1992.	
	CP	KIMMEL JR, Pollock HG, and Hazelwood RL. Isolation and characteriza-tion of chicken insulin. Endocrinology 83: 1323-1330, 1968.	
	CQ	LEE CC and Miller RJ. Is there really an NPY Y3 receptor? Regul Pept 75-76: 71-78, 1998.	
	CR	MARTINEZ V, Barquist E, Rivier J, and Tache Y. Central CRF inhibits gastric emptying of a nutrient solid meal in rats: the role of CRF2 recep-tors. Am J Physiol 274: G965-970, 1998.	
	CS	MEDEIROS MD and Turner AJ. Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopepti-dase-24.11. Endocrinology 134: 2088-2094, 1994.	
	CT	PAPPAS TN, Debas HT, Chang AM, and Taylor IL. Peptide YY release by fatty acids is sufficient to inhibit gastric emptying in dogs. Gastroen-terology 91: 1386-1389, 1986.	
	CU	PAPPAS TN, Debas HT, and Taylor IL. Peptide YY: metabolism and ef-fect on pancreatic secretion in dogs. Gastroenterology 89: 1387-1392, 1985.	
	CV	STANLEY BG, Daniel DR, Chin AS, and Leibowitz SF. Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion. Peptides 6: 1205-1211, 1985.	
	CW	TATEMOTO K. Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc Natl Acad Sci U S A 79: 2514-2518, 1982.	
	CX	TATEMOTO K, Carlquist M, and Mutt V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypep-tide. Nature 296: 659-660, 1982.	
	CY	WAHLESTEDT C, Yanaihara N, and Hakanson R. Evidence for different pre- and postjunctional receptors for neuropeptide Y and related peptides. Regul Pept 13: 307-318, 1986.	
	CZ	WHITCOMB DC and Taylor IL. A new twist in the brain-gut axis. Ameri-can Journal of the Medical Sciences 304: 334-338, 1992.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/590,634-Conf. #2264
				Filing Date	May 17, 2007
				First Named Inventor	Bjarne Larsen
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	66123(300586)

	CA1	ALBRECHT JT and Canada TW. Cachexia and anorexia in malignancy. Hemato Oncol Clin North Am 10: 791-800, 1996.	
	CB1	NELSON KA, Walsh D, and Sheehan FA. The cancer anorexia-cachexia syndrome. J Clin Oncol 12: 213-225, 1994.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--